EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

Design and in silico modeling of new phosphatydilinositol 3-kinases and histone deacetylases dual inhibitors

Emir Kukić, Milan Beljkaš, Marija Popović-Nikolić, Katarina Nikolić, Slavica Oljačić

Arhiv za farmaciju · 2026 · 76 (5) · 279-297

DOI: 10.5937/arhfarm76-69790 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arhiv za farmaciju, 2026. Verfasst von Emir Kukić und 4 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0). Gefördert von: Ministry of Education, Science and Technological Development of the Republic of Serbia.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the aim of simultaneously modulating the epigenetic system and the lipid kinase pathway, histone deacetylase 6 (HDAC6) and phosphatidylinositol 3-kinases (PI3K) were selected as target enzymes for the design of potential anticancer agents. Novel PI3K/HDAC inhibitors were designed by integrating pharmacophoric features important for the inhibition of both enzymes into a single molecular framework. Several in silico methodologies, including molecular docking, ADMET profiling and quantum chemical simulations were applied to select the best candidate for further synthesis and biological evaluation. Compound PI3K/HDAC-4 emerged as the most promising designed structure, establishing all key interactions with HDAC6 and PI3K isoforms, while exhibiting favorable ADMET properties and a balanced electronic profile as confirmed by density functional theory (DFT) analysis. The proposed in silico protocol represents a promising starting point for the development and further optimization of multi-target PI3K/HDAC inhibitors as potential anticancer agents.

Förderung

  • Ministry of Education, Science and Technological Development of the Republic of Serbia

Zitieren

APA

Kukić, E., Beljkaš, M., Popović-Nikolić, M., Nikolić, K., & Oljačić, S. (2026). Design and in silico modeling of new phosphatydilinositol 3-kinases and histone deacetylases dual inhibitors. Arhiv za farmaciju, 76(5), 279-297. https://doi.org/10.5937/arhfarm76-69790

Vancouver

Kukić E, Beljkaš M, Popović-Nikolić M, Nikolić K, Oljačić S. Design and in silico modeling of new phosphatydilinositol 3-kinases and histone deacetylases dual inhibitors. Arhiv za farmaciju. 2026;76(5):279-297. doi:10.5937/arhfarm76-69790

BibTeX
@article{Kuki2026,
  author = {Kukić, Emir and Beljkaš, Milan and Popović-Nikolić, Marija and Nikolić, Katarina and Oljačić, Slavica},
  title = {Design and in silico modeling of new phosphatydilinositol 3-kinases and histone deacetylases dual inhibitors},
  journal = {Arhiv za farmaciju},
  year = {2026},
  volume = {76},
  number = {5},
  pages = {279--297},
  doi = {10.5937/arhfarm76-69790}
}
Kostenlos starten →